問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Radiation Therapy

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

林慶雄
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

59Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林慶雄

CHANGHUA CHRISTIAN HOSPITAL

Division of Thoracic Medicine

List

58Cases

2022-02-01 - 2028-02-15

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-09-01 - 2024-07-15

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-02-06 - 2029-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2017-02-10 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Recruiting13Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張家崙
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Hematology & Oncology

2022-11-01 - 2025-01-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2022-11-01 - 2025-04-14

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

  • Condition/Disease

    Small-Cell Lung Cancer (SCLC)

  • Test Drug

    Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿
China Medical University Hospital-Taipei

未分科

2021-08-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-06-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-02-01 - 2018-06-30

Phase III

A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX/011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

  • Condition/Disease

    Advanced or metastatic (Stage IV) non-small cell lung cancer (NSCLC)

  • Test Drug

    Custirsen

Participate Sites
6Sites

Terminated6Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB